MaaT Pharma, a clinical-stage biotechnology company focused on Microbiome Ecosystem Therapies (MET) for cancer patients, has secured a €37.5 million loan from the European Investment Bank (EIB) to advance its late-stage hemato-oncology programs.
This funding will support Xervyteg (MaaT013), currently under review by the European Medicines Agency (EMA) for acute Graft-versus-Host Disease (aGvHD), and facilitate the development of MaaT033, which is in a Phase 2b trial for allogeneic stem cell transplant patients.
MaaT Pharma has made significant progress, completing enrollment for the ARES trial of Xervyteg in October 2024 and submitting its Marketing Authorization Application to the EMA in June 2025. The company also finalized an exclusive distribution agreement with Clinigen for Europe.
Advisors: MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor.
KEY QUOTE:
“We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma’s growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg(MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company’s financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.”
Eric Soyer, Chief Financial Officer, MaaT Pharma
